HAEMONETICS CORP — Director's Dealing 2024

May 29, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-28

Reporting Person: Basil Michelle L (EVP and General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-28	Common Stock	A	24748	—	Acquired	56005	Direct
2024-05-28	Common Stock	F	11758	$95.73	Disposed	44247	Direct
2024-05-29	Common Stock	S	8896	$87.86	Disposed	35351	Direct
2024-05-29	Common Stock	S	4094	$88.57	Disposed	31257	Direct

Footnotes

F1: Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.

F2: This number includes unvested restricted stock units ("RSUs") previously reported.

F3: Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.

F4: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.28 to $88.28, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5) and (6) to this Form 4.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.29 to $88.92, inclusive.